Clinical Trial

A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a single-center, open-label Phase II clinical study to evaluate the antiviral activity and immune responses of AHB-137 injection in participants with CHB treated with nucleos (t) ide analogues.
Protocol Amendment History 5 changes
notable Primary completion pushed: 2026-07-17 -> 2027-07-27 2026-08-11
minor Completion pushed: 2027-02-09 -> 2027-11-27 2026-08-11
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-05
notable Enrollment reduced: 30 -> 20 participants 2026-05-05
minor Completion pushed: 2026-12-01 -> 2027-02-09 2026-05-05
Trial Details
NCT Number NCT06993480
Lead Sponsor Ausper Biopharma Co., Ltd.
Conditions Chronic Hepatitis B
Enrollment 20 participants
Start Date 2025-07-15
Primary Completion 2027-07-27 (estimated)
Study Completion 2027-11-27 (estimated)
Updated on ClinicalTrials.gov 2026-08-10